The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
 
Rachel Frascati
No Relationships to Disclose
 
Amy P. Early
No Relationships to Disclose
 
Mary E. Reid
Consulting or Advisory Role - Janssen Oncology
 
Kelvin Lee
Research Funding - Bristol Myer Squibb
 
Jason Muhitch
Patents, Royalties, Other Intellectual Property - Health Research, Inc.
 
Circe Mesa
Other Relationship - Center for Molecular Immunology - makers of CIMAvax-EGF
 
Patricia Lorenzo Luaces
Other Relationship - Center for Molecular Immunotherapy - makers of CIMAvax-EGF
 
Orestes Santos-Morales
Other Relationship - CIMAvax-EGF
 
Askia Dozier
No Relationships to Disclose
 
Igor Puzanov
Stock and Other Ownership Interests - Celldex; Celldex (I)
Consulting or Advisory Role - Amgen; Iovance Biotherapeutics; Merck; Nektar; Nouscom; Oncorus; Roche; Seneca Therapeutics
 
Christos Fountzilas
Research Funding - Aravive (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bellicum Pharmaceuticals (Inst); Bristol-Myers Squibb/Ono Pharmaceutical (Inst); Corcept Therapeutics (Inst); CrystalGenomics (Inst); Dragonfly Therapeutics (Inst); ERYTECH Pharma (Inst); Incyte (Inst); Ipsen (Inst); Kadmon (Inst); Kinex (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Syndax (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
 
Shipra Gandhi
(OPTIONAL) Uncompensated Relationships - AstraZeneca
 
Kristopher Attwood
No Relationships to Disclose
 
Alan Hutson
No Relationships to Disclose
 
Candace S. Johnson
No Relationships to Disclose
 
Zaima Herrera
Other Relationship - CIMAvax-EGF
 
Danay Saavedra
Other Relationship - CIMAvax-EGF
 
Kalet Leon
Other Relationship - CIMAvax-EGF
 
Tania Crombet Ramos
Other Relationship - CIMAvax-EGF
 
Grace K. Dy
Consulting or Advisory Role - Amgen; AstraZeneca; Lilly; Mirati Therapeutics
Research Funding - AMGEN (Inst); AstraZeneca (Inst); Bioatla (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); regeneron (Inst); Revolution Medicines (Inst); Sanofi (Inst)